Citius Oncology CTOR
NASDAQ CTOR
$0.56 0.00 (-0.71%)
As of: Nov 11, 2026 · 3:59 PM EST

Citius Oncology (CTOR) Non Operating Interest Expenses (2025 - 2026)

Updated

Citius Oncology's Non Operating Interest Expenses was $231,732 in fiscal Q3 2026 (quarter ended Jun 30, 2026), up 44.2% from $160,755 a year earlier and up 601.6% from the prior quarter.

Analysis

Citius Oncology (CTOR) Non Operating Interest Expenses (2025 - 2026) Analysis & Trends

On a trailing twelve-month basis, Citius Oncology's Non Operating Interest Expenses was $367,881 through Jun 30, 2026; for FY2025 (ended Sep 30, 2025), it was $218,032.

  • Per Business Quant data, CTOR's Non Operating Interest Expenses in the three fiscal quarters before Q3 2026 was $33,031 (Q2 2026), $45,841 (Q1 2026) and $57,277 (Q4 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non Operating Interest Expenses (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn -
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn 217.00 Mn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn -
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn -
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn -477.00 Mn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn 653.00 Mn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn 269.00 Mn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn -
10 Citius Oncology 60.42 Mn 30.00 Mn 1.00 Mn 231,732.00
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 231,732.00
Mar 31, 2026 33,031.00
Dec 31, 2025 45,841.00
Sep 30, 2025 57,277.00
Jun 30, 2025 160,755.00
API Access

Citius Oncology Non Operating Interest Expenses API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=non-operating-interest-expenses&ticker=CTOR&period=max&api_key=YOUR_API_KEY